Interview with RESI JPM Sponsor, Bullfrog AI 

13 Mar

By Caitlin Dolegowski, Marketing Manager, LSN

CaitiBullfrog AI is at the forefront of integrating artificial intelligence into drug development, helping biotech and pharma companies extract meaningful insights from complex data. Toby Sayre shares how the company’s AI-driven approach enhances decision-making, accelerates therapeutic innovation, and improves success rates. In this interview, he discusses Bullfrog AI’s technology, its role in shaping the future of drug development, and the company’s experience at RESI.

Secure your sponsorship or exhibitor package today. Contact the LSN Business Development Team to find the best fit for your brand and maximize your impact at RESI in 2025.

Hot Investor Mandate: Asia-Based VC Firm Invests in Early and Growth-Stage Medtech, Digital Health, and Technologies Leveraging AI on a Global Scale

11 Mar

A globally diversified healthcare venture capital firm has a mission is to deliver medical solutions and savings to over 100M people around the world. The firm seeks out visionary entrepreneurs who combine integrity, intelligence, and passion to address pressing healthcare challenges innovatively and ethically. The firm’s globally diversified portfolio comprises 60% allocation in the U.S. and the remaining 40% distributed across Singapore, India, and the EU. The firm’s engagement extends beyond financial investment. The firm provides robust post-investment support, focusing on strategy development, distribution, cross-border expansion, and manufacturing/OEM partnerships. They strive to establish an ecosystem that fosters collaboration among start-ups, government bodies, clinical, investment, and commercial partners. This approach ensures that portfolio companies receive comprehensive support, aiding in their growth and impactful contribution to the healthcare sector. 
 
Focused on early to growth-stage investments, the firm specializes in sectors including medical devices, digital health, healthcare services, and AI-empowered solutions. The firm has particular interests in critical areas such as oncology, ophthalmology, brain health, orthopedics, cardiology, and other chronic diseases management. 
 
The firm does not have specific management team requirements. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: VC Firm Invests in Medical Devices, Software-Enabled Healthtech, and Deeptech With Focus on Europe-Based Companies

11 Mar

A deep tech and medical-focused venture capital firm based in Europe typically participates in early-stage, Seed to Series A financing rounds, with check sizes averaging between 1M and 1.5M EUR. Follow-on investment is possible. The firm seeks opportunities across Europe, excluding the UK, and is flexible in both leading and co-investing. The firm can be an active investor and may seek board or observer seats on a case-by-case basis. 
 
The firm is interested in medical devices, software, manufacturing and AI/machine learning related technologies. The firm also seeks novel approaches in tech bio, such as technologies that support drug discovery, drug development, expedite clinical trials, or gather real-world data. Other areas of interest include new genomic analysis. Traditional therapeutics are not of interest. The firm prefers to engage with companies early, and could interact with companies 1–2 years before the seed stage. 
 
The firm does not have specific requirements for a company’s founding team but prefers teams with diverse gender representation. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: USA-Based VC Firm Seeks Life Science and Deeptech Companies, Investing in Over 20 Companies Per Year Across the Globe

11 Mar

A venture capital firm headquartered in the US focuses on investing in early stage, typically pre-seed to Series A, across deeptech, life sciences, and the intersection between technology and healthcare in the U.S. market. The firm is backed by companies and family offices in the U.S., Europe, and Singapore, with partners that are all entrepreneurs in the life science space. The firm will usually co-invest with typical check sizes ranging from $100k-1M. The firm also partners with LPs for acquisition opportunities, and in those cases, they will do deals up to $100M but it is acquiring the company as opposed to investing. The firm plans to invest in 20 global companies per year in addition to incubating 1-2 companies a year. The firm is also willing to help companies go into emerging areas like Africa and Asia. 
 
The firm is opportunistic for life science and deeptech investments. Big focus areas for the firm include AI, health tech, neuroscience, life sciences tools, and therapeutics in the early-stage. The firm is also open to orphan diseases. In terms of therapeutics, the firm will invest in companies that are Pre-Clinical to Phase I. 
 
The firm does not have management team requirements and does not require taking a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: VC Firm Invests in Seed and Series A Rounds in Women’s Health Companies Focusing on Europe, Middle East, and US

11 Mar

A women-led venture capital firm is dedicated to women’s health and have invested in over 10 companies in this space. The firm is looking to invest in life science companies that address women’s health between Seed to Series A in Europe, the UK, and Israel, eventually scaling to the U.S as well. The firm is open to acting as a lead investor for smaller rounds, however they are currently co-investing especially as they start to invest in the U.S. 
 
The firm is open to any life science sector including therapeutics, diagnostics, medical devices, digital health, etc. in the clinical stage as long as the company addresses women’s health. This includes innovations that solely, disproportionately, and/or differently affect women, such as menopause, autoimmune diseases, and heart disease. The firm is open to anywhere from therapeutics and genomics to consumer products. The firm requires to see clinical data and efficacy in the technology. In terms of medical devices, the firm is open to all classes. The only exception that the firm does not invest in is pharmaceuticals. 
 
The firm does not have specific team requirements, however the firm will take a board seat. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Partnering is Open for RESI Europe – Connect with Global Investors 

11 Mar

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wpPartnering for RESI Europe, co-organized with Biocat, is now live. As of March 10, the system is already buzzing with activity, demonstrating the strong demand for early-stage deals. The conference begins with an in-person RESI Europe event on April 1 in Barcelona at the InterContinental Hotel, followed by two days of virtual partnering on April 2-3.

This is a key opportunity for life science startups, investors, and strategic partners to connect on a global level. RESI offers flexible registration options, including a one-day in-person pass, two-day virtual access, or full participation across all three days. The RESI partnering platform is unique, utilizing the LSN Investor and Licensing Partner database to ensure that companies can identify which investors are the best fit before requesting a meeting.

There is still plenty of time to register and start booking meetings with investors actively seeking early-stage technologies. RESI is a truly global event, and we encourage you to attend the upcoming partnering tutorial to make the most of the platform.

March 18, 2025 11:00 AM ET
RESI Europe Partnering Tutorial – Sign up 

Unprecedented Growth of Life Science Investment & Startups in Catalonia/Barcelona

11 Mar

By Sougato Das, President and COO, Life Science Nation (LSN)

Sougato-DasThe Barcelona and the Catalonia region of Spain achieved record investment in life sciences startups, venture, and growth companies in 2024. Catalonia hosts the HQs of 1500 life science companies, of which 90% are early stage/startups – an average of 1.25 startups are created in the region weekly. Combined with commensurate increases in scientific publications (over 54K, ranked 5th in Europe), clinical trials, and other bibliometric measures, Catalonia is becoming a major life science hub in Europe, with 25% of Spain’s life science companies. With RESI Europe, the largest life science investor event in the EU in terms of number of attending investors, taking place April 1 – 3, the trend is positioned to continue in 2025.

In fact, Catalonian life science seed, venture, and growth companies received €350 million in investment in 2024. The increasing draw of the region for Spanish investors, pan-European investors, Asian investors, and US investors can be seen not only across investments, but also across conference participation. 80% of the investment is from VCs, with 75% from investors outside of Spain, including prestigious firms like Sofinnova Partners, Merck, and Novartis Venture Fund. The remaining 20% of the investment is from non-dilutive sources. Not to be outdone, M&A activity also hit a record for the region, with 11 life science M&A deals.

In terms of modality, medtech has led in gross investment amount, primarily due to Impress (dental health). Next was biotech, accounting for €143 million. Digital health investment, however, saw a drop of 40% vs. 2023. This is likely due to the digital health sector experiencing rapid growth in 2023, with a 61% increase from 2022 – most first-round investments were likely made in digital health during that time and now the receiving companies are engaged in the funded R&D. Catalonia also boasts 71 investment organizations.

Finally, Catalonia is a hotbed of clinical trial activity, host to 87% of trials in Spain. The plurality (one-third) of these trials are in oncology. Recognizing this potential, global pharmaceutical and life sciences leaders have set up production centers and R&D departments in Catalonia, taking advantage of the region’s exceptional pool of local talent. Now is the time to take advantage of RESI Europe to partner with international investors, if you are local to Spain, or get your bearings in the booming Catalonia life science sector if you are new to the region.

← Older Entries
Newer Entries →